KR20060023959A - 아밀로이드 플라크 관련 상태의 치료용 ｎｏｇｏ-수용체길항자 - Google Patents

아밀로이드 플라크 관련 상태의 치료용 ｎｏｇｏ-수용체길항자 Download PDF

Info

Publication number
KR20060023959A
KR20060023959A KR1020057019510A KR20057019510A KR20060023959A KR 20060023959 A KR20060023959 A KR 20060023959A KR 1020057019510 A KR1020057019510 A KR 1020057019510A KR 20057019510 A KR20057019510 A KR 20057019510A KR 20060023959 A KR20060023959 A KR 20060023959A
Authority
KR
South Korea
Prior art keywords
seq
ngr1
nogo receptor
mammalian
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057019510A
Other languages
English (en)
Korean (ko)
Inventor
스테펀 엠. 스트리트매터
다니엘 에이치. 에스. 리
웨이웨이 리
Original Assignee
예일 유니버시티
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예일 유니버시티, 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 예일 유니버시티
Publication of KR20060023959A publication Critical patent/KR20060023959A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020057019510A 2003-04-16 2004-04-16 아밀로이드 플라크 관련 상태의 치료용 ｎｏｇｏ-수용체길항자 Withdrawn KR20060023959A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46342403P 2003-04-16 2003-04-16
US60/463,424 2003-04-16

Publications (1)

Publication Number Publication Date
KR20060023959A true KR20060023959A (ko) 2006-03-15

Family

ID=33310776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057019510A Withdrawn KR20060023959A (ko) 2003-04-16 2004-04-16 아밀로이드 플라크 관련 상태의 치료용 ｎｏｇｏ-수용체길항자

Country Status (15)

Country Link
US (1) US20070065429A1 (https=)
EP (1) EP1615654A2 (https=)
JP (1) JP2006523708A (https=)
KR (1) KR20060023959A (https=)
CN (1) CN1832752A (https=)
AU (1) AU2004231742A1 (https=)
BR (1) BRPI0409562A (https=)
CA (1) CA2522649A1 (https=)
EA (1) EA009643B1 (https=)
IS (1) IS8081A (https=)
MX (1) MXPA05011100A (https=)
NO (1) NO20055392L (https=)
RS (1) RS20050774A (https=)
WO (1) WO2004093893A2 (https=)
ZA (1) ZA200509242B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
CA2555018A1 (en) * 2004-01-30 2005-08-18 Biogen Idec Ma Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
US8269141B2 (en) 2004-07-13 2012-09-18 Lincoln Global, Inc. Power source for electric arc welding
US9956639B2 (en) 2005-02-07 2018-05-01 Lincoln Global, Inc Modular power source for electric ARC welding and output chopper
US9855620B2 (en) 2005-02-07 2018-01-02 Lincoln Global, Inc. Welding system and method of welding
US9647555B2 (en) 2005-04-08 2017-05-09 Lincoln Global, Inc. Chopper output stage for arc welder power source
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
EP2081429A4 (en) * 2006-08-31 2010-01-06 Biogen Idec Inc PROCESS FOR PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
NZ525422A (en) * 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
JP2005507246A (ja) * 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists

Also Published As

Publication number Publication date
BRPI0409562A (pt) 2006-04-18
WO2004093893A2 (en) 2004-11-04
IS8081A (is) 2005-10-21
CA2522649A1 (en) 2004-11-04
JP2006523708A (ja) 2006-10-19
AU2004231742A2 (en) 2004-11-04
EA200501620A1 (ru) 2006-06-30
RS20050774A (sr) 2007-12-31
NO20055392L (no) 2005-11-15
EA009643B1 (ru) 2008-02-28
US20070065429A1 (en) 2007-03-22
CN1832752A (zh) 2006-09-13
MXPA05011100A (es) 2006-04-18
ZA200509242B (en) 2006-12-27
AU2004231742A1 (en) 2004-11-04
EP1615654A2 (en) 2006-01-18
WO2004093893A3 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
US7731963B2 (en) TWEAK receptor agonists as anti-angiogenic agents
CN104053452B (zh) 用于抑制经由胰岛素样生长因子-1的细胞活化的方法
JP5184367B2 (ja) 抗アルファ２インテグリン抗体およびその使用
CA2519528A1 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
CA2734694A1 (en) Methods for inhibiting ocular angiogenesis
US20060171952A1 (en) JAM-3 and antibodies that bind thereto
US20070065429A1 (en) Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
CA2401993A1 (en) Human monoclonal antibodies against oxidized ldl receptor and pharmaceutical uses thereof
US20150239973A1 (en) Modulation of the Interaction Between SorLA and GDNF-Family Ligand Receptors
AU2001289019B2 (en) Tweak receptor agonists as anti-angiogenic agents
AU2001289019A1 (en) Tweak receptor agonists as anti-angiogenic agents
JP2007515159A (ja) 血管形成阻害分子、並びに癌の治療及び診断におけるその使用
WO2001015729A9 (en) Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses
AU2005210621B2 (en) Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
JP4897490B2 (ja) 転移抑制のための抗ｐｅｃａｍ治療
MXPA06008392A (es) Tratamiento de condiciones las cuales implican degeneracion neuronal dopaminergica usando antagonistas de receptores nogo

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid